Contact us
 |
[email protected] |
 |
3275638434 |
 |
 |
| Paper Publishing WeChat |
Useful Links
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Article
Ceritinib: From Synthesis to Clinical Applications
Author(s)
Xiuyan Cui, Weihua Song, Qi Yang and Zhangqun Yang
Full-Text PDF
XML 12423 Views
DOI:10.17265/2328-2150/2016.08.005
Affiliation(s)
ABSTRACT
Lung cancer is the major cause of cancer-related mortality,
accountingfor over one quarter of cancer deaths. Lung cancers are generally
divided into two main categories: SCLC (small cell lung cancer) and NSCLC
(non-small cell lung cancer). NSCLC accounts for
approximately 85% of all lung cancers. ALK (anaplastic largecell kinase) gene
rearrangements are identified and targeted resulting in promising response
rates for NSCLC in early studies. Ceritinib is a second-generation ALK
inhibitor that has demonstrated activity in crizotinib (the first-generation
ALK inhibitor)-resistant patients. In this paper, the synthesis, pharmacodynamics, pharmacokinetics, therapeutic trials,
adverse events and drug-drug interactions are briefly overviewed in order to
make more scholars, medical workers and patients have a more clear and
comprehensive recognition on this drug.
KEYWORDS
Ceritinib, non-small cell lung cancer, ALK inhibitor, review.
Cite this paper
Cui, X., et al. 2016. “Ceritinib: From Synthesis to Clinical Applications.” Journal of Pharmacy and Pharmacology 4 (8): 390-393.
References